Proteomics in cancer research

With the human genome sequence now determined, the field of molecular medicine is moving beyond genomics to proteomics. In the field of cancer research, the key question is: how can oncologists best use techniques of proteomics in basic research and clinical application? In the postgenomic era, proteomics promises the discovery of biomarkers and tumor markers for early detection and diagnosis, novel protein-based drug targets for anticancer therapy, and new endpoints for the assessment of therapeutic efficacy and toxicity. This review paper will explore key themes in proteomics and their application in clinical cancer research.

Download Full-text

Detection of Leukemia Using Image Processing

International Journal of Advanced Research in Computer Science and Software Engineering ◽

10.23956/ijarcsse.v8i4.632 ◽

2018 ◽

Vol 8 (4) ◽

pp. 61

Author(s):

A. Sivasangari ◽

G. Sasikumar

Keyword(s):

Image Processing ◽

Statistical Analysis ◽

Early Detection ◽

Visual Inspection ◽

Causes Of Death ◽

Cure Rate ◽

Blood Disorders ◽

Detection And Diagnosis ◽

The Moment ◽

Early Detection And Diagnosis

Leukemia disease is one of the leading causes of death among human. Its cure rate and prognosis depends mainly on the early detection and diagnosis of the disease. At the moment, identification of blood disorders is through visual inspection of microscopic images by examining changes like texture, geometry, colour and statistical analysis of images . This project aims to preliminary of developing a detection of leukemia types using microscopic blood sample using MATLAB. Images are used as they are cheap and do not expensive for testing and lab equipment.

Download Full-text

Early Detection and Diagnosis of Lung Cancer and Immune Circuit~!2008-10-20~!2008-11-07~!2008-12-05~!

The Open Lung Cancer Journal ◽

10.2174/1876819900801010001 ◽

2008 ◽

Vol 1 (1) ◽

pp. 1-12

Author(s):

Oleg Kshivets

Keyword(s):

Lung Cancer ◽

Early Detection ◽

Detection And Diagnosis ◽

Diagnosis Of Lung Cancer ◽

Early Detection And Diagnosis

Download Full-text

Syndecans and Pancreatic Ductal Adenocarcinoma

Biomolecules ◽

10.3390/biom11030349 ◽

2021 ◽

Vol 11 (3) ◽

pp. 349

Author(s):

Nausika Betriu ◽

Juan Bertran-Mas ◽

Anna Andreeva ◽

Carlos E. Semino

Keyword(s):

Extracellular Matrix ◽

Pancreatic Ductal Adenocarcinoma ◽

Cell Types ◽

Ductal Adenocarcinoma ◽

Physiological Processes ◽

Extracellular Matrix Components ◽

Detection And Diagnosis ◽

And Migration ◽

Early Detection And Diagnosis

Pancreatic Ductal Adenocarcinoma (PDAC) is a fatal disease with poor prognosis because patients rarely express symptoms in initial stages, which prevents early detection and diagnosis. Syndecans, a subfamily of proteoglycans, are involved in many physiological processes including cell proliferation, adhesion, and migration. Syndecans are physiologically found in many cell types and their interactions with other macromolecules enhance many pathways. In particular, extracellular matrix components, growth factors, and integrins collect the majority of syndecans associations acting as biochemical, physical, and mechanical transducers. Syndecans are transmembrane glycoproteins, but occasionally their extracellular domain can be released from the cell surface by the action of matrix metalloproteinases, converting them into soluble molecules that are capable of binding distant molecules such as extracellular matrix (ECM) components, growth factor receptors, and integrins from other cells. In this review, we explore the role of syndecans in tumorigenesis as well as their potential as therapeutic targets. Finally, this work reviews the contribution of syndecan-1 and syndecan-2 in PDAC progression and illustrates its potential to be targeted in future treatments for this devastating disease.

Download Full-text

GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions

Cancers ◽

10.3390/cancers13030493 ◽

2021 ◽

Vol 13 (3) ◽

pp. 493

Author(s):

Riccardo Di Fiore ◽

Sherif Suleiman ◽

Bridget Ellul ◽

Sharon A. O’Toole ◽

Charles Savona-Ventura ◽

...

Keyword(s):

Cancer Research ◽

Gynecological Cancer ◽

Gynecologic Cancer ◽

Delayed Diagnosis ◽

Research Programme ◽

Basic Research ◽

Diagnosis And Treatment ◽

Rare Cancer ◽

Cost Action ◽

Gynecologic Tumors

More than 50% of all gynecologic tumors can be classified as rare (defined as an incidence of ≤6 per 100,000 women) and usually have a poor prognosis owing to delayed diagnosis and treatment. In contrast to almost all other common solid tumors, the treatment of rare gynecologic tumors (RGT) is often based on expert opinion, retrospective studies, or extrapolation from other tumor sites with similar histology, leading to difficulty in developing guidelines for clinical practice. Currently, gynecologic cancer research, due to distinct scientific and technological challenges, is lagging behind. Moreover, the overall efforts for addressing these challenges are fragmented across different European countries and indeed, worldwide. The GYNOCARE, COST Action CA18117 (European Network for Gynecological Rare Cancer Research) programme aims to address these challenges through the creation of a unique network between key stakeholders covering distinct domains from concept to cure: basic research on RGT, biobanking, bridging with industry, and setting up the legal and regulatory requirements for international innovative clinical trials. On this basis, members of this COST Action, (Working Group 1, “Basic and Translational Research on Rare Gynecological Cancer”) have decided to focus their future efforts on the development of new approaches to improve the diagnosis and treatment of RGT. Here, we provide a brief overview of the current state-of-the-art and describe the goals of this COST Action and its future challenges with the aim to stimulate discussion and promote synergy across scientists engaged in the fight against this rare cancer worldwide.

Download Full-text